Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system

Artificial Organs

Volumn 31, Issue 3, 2007, Pages 193-199

  Tan, Han Khim ^a   Yang, Wen Shin ^a   Chow, Pierce ^a   Lui, Hock Foong ^a   Choong, Hui Lin ^a   Wong, Kok Seng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Dialysis; Liver failure; Renal failure

Indexed keywords

BLOOD PRESSURE; DISEASES; GLYCOPROTEINS; MERCURY COMPOUNDS; PATIENT TREATMENT; POLYSACCHARIDES; UREA;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTI-COAGULATION; BLOOD PURIFICATION; LIVER FAILURE; LOW DOSE; MINIMISATION; PROTHROMBIN TIME; RECIRCULATING SYSTEM; RENAL FAILURE; UNFRACTIONATED HEPARINS;

DIALYSIS;

AMMONIA; BILIRUBIN; CREATININE; HEPARIN; SODIUM CHLORIDE; UREA;

ADULT; AGED; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; ANTICOAGULATION; APACHE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BLOOD VESSEL OCCLUSION; CASE REPORT; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIALYSIS EQUIPMENT AND SUPPLIES; DIASTOLE; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; MALE; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPY; SEROLOGY; SYSTOLE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UREA BLOOD LEVEL; VASCULAR ACCESS;

EID: 33847636826     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2007.00364.x     Document Type: Article

References (25)

1. Kurtovic J, Riordan SM, Williams R. Fulminant hepatic failure. Curr Treat Options Gastroenterol 2005;8:503-18.
2. Sarwar S, Khan AA, Alam A, et al. Predictors of fatal outcome in fulminant hepatic failure. J Coll Physicians Surg Pak 2006;16:112-6.
3. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006;55:98-104.
4. Skwarek A, Grodzicki M, Nyckowski P, et al. The use of Prometheus FPSA system in the treatment of acute liver failure: preliminary results. Transplant Proc 2006;38:209-11.
5. Mitzner S, Loock J, Peszynski P, et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS - a review of clinical, biochemical and electrophysiological data. Metab Brain Dis 2002;17:463-75.
6. Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-30.
7. Awad SS, Swaniker F,Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001;130:354-62.
8. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. Clin Nephrol 2002;58:376-83.
9. De Vos JY. Anticoagulation therapy in acute renal failure extracorporeal treated patients.EDTNA ERCA J 2002; Suppl. 2:30-3.
10. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous venovenous haemofiltration. Intensive Care Med 2003;29:575-8.
11. Doria C, Mandala L, Scott VL, Gruttadauria S, Marino IR. Fulminant hepatic failure bridged to liver transplantation with a molecular adsorbent recirculating system: a single-center experience. Dig Dis Sci 2006;51:47-53.
12. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
13. Faybik P, Bacher A, Kozek-Langenecker SA, et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 2006;10:R24. doi:10.1186/cc3985.
14. Davenport A,Will EJ,Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994;66:431-7.
15. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004;50:76-80.
16. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000;26:1652-7.
17. Tan HK. Molecular adsorbent recirculating system (MARS). Ann Acad Med Singapore 2004;33:329-35.
18. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. LiverTranspl 2005;11:1581-9.
19. Pavese P, Bonadona A, Beaubien J, et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005;52:26-9.
20. Kelly DA. Managing liver failure. Postgrad Med J 2002;78:660-7.
21. Novelli G, Rossi M, PretagostiniM, et al. One hundred sixteen cases of acute liver failure treated with MARS. Transpl Proc 2005;37:2557-9.
22. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003;16:566-71.
23. Holt AW, Bierer P, Glover P, Plummer JL, Bersten AD. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med 2002;28:1649-55.
24. Ramesh Prasad GV, Palevsky PM, Burr R, Lesko JM, Gupta B, Greenberg A. Factors affecting system clotting in continuous renal replacement therapy: results of a randomized controlled trial. Clin Nephrol 2000;53:55-60.
25. Charif R, Davenport A. Heparin-induced thrombocytopenia: an uncommon but serious complication of heparin use in renal replacement therapy. Hemodial Int 2006;10:235-40.